Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, its adoption is restricted by a complicated dosing protocol that necessitates administration while fasting with water, as well as the avoidance of food or medications for a minimum of 30 min afterward. Such requirements reduce convenience and compromise adherence in routine practice [11, 16].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [16]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Pharmacologically, long-acting GLP-1 receptor agonists (GLP-1RAs) exhibit glucoregulatory functions via a triumvirate of mechanisms, namely, stimulation of insulin release in a glucose-dependent manner, suppression of glucagon activity during hyperglycemia, and a minor delay of gastric emptying resulting in slower glu…”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“In line with this, recent advancements in fatty acid acylation– based protraction technology have provided the possibility of achieving extended plasma half-lives (t1⁄2) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analog with a t1⁄2 of ~1 week in humans (8).”
BackgroundSelf-citationThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“In addition, GLP-1 promotes satiety and reduces energy intake by virtue of its neurotransmitter role in brainstem-hypothalamus pathways signaling satiety (3, 4), and some long-acting GLP-1RAs including semaglutide have shown cardiovascular risk reduction (5, 6).”
BackgroundSelf-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationpH stability and activity curves of pepsin with special reference to their clinical importance.
Piper, D. W., & Fenton, B. H. (1965) · Gut · doi:10.1136/gut.6.5.506 · Cited by 385
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Cited by
Items 501–599 of 599
Twin- und Trinkretine: Balanceakt zwischen Diabetes und Adipositas?
Stirban, O. A. (2024) · Info Diabetologie · doi:10.1007/s15034-023-4900-z
Rico-Fontalvo, J. E., Daza-Arnedo, R., Vázquez, L. C., Yánez, T. R., Raad-Sarabia, M., Toapanta, N., Rafael-Vicente, P., Montejo-Hernández, J. D., & Soler, M. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.23000052
Lv, Z., Luo, Q., Tang, Z., Lv, X., Wu, T., Huang, L., & Tang, C. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1186
The developmental trajectory of GLP-1 receptor agonists
Kou, B., & Qian, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00001-2
Alshammari, W. M. D., & Al-Qahtani, K. S. (2025) · Saudi Journal of Medical and Pharmaceutical Sciences · doi:10.36348/sjmps.2025.v11i04.008
de Oliveira, B. V., Franco, P. H. M., Nogueira, M. C., & Faria, M. A. G. (2025) · International Journal of Nutrology · doi:10.54448/ijn25207
Okamoto, A., Yokokawa, H., Morimoto, A., Goto, K., Fukuda, H., Hisaoka, T., & Naito, T. (2025) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2025.152007
Stabilization of Self-Pressurized Gelatin Capsules for Oral Delivery of Biologics
Wood‐Yang, A. J., Palacios, J. I., Sankaranarayanan, A., & Prausnitz, M. R. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091156
Byrn, S. R., Zografi, G., & Chen, X. (. (2025) · Wiley eBooks · doi:10.1002/9781394254484.ch25
Pharmacology and Clinical Efficacy of Semaglutide in the Management of Type 2 Diabetes Mellitus
Naga Lakshmi, A., Dhana Lakshmi, G., Durga Naresh Kumar, G., Meghana, A., Gangadhar, J., & Anusha, G. (2025) · Journal of Pharma Insights and Research. · doi:10.69613/9dd27k52
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031555
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031567
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031546
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031564
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031558
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031549
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031561
Bao, X., Qian, K., Xu, M., Chen, Y., Wang, H., Pan, T., Wang, Z., Yao, P., & Lin, L. (2024) · Figshare · doi:10.6084/m9.figshare.26561800
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031552
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031570
Aktuelle Therapiekonzepte und Entwicklungen in der Diabetes mellitus Typ 2-Therapie
Honskamp, A. K. (2021) · Unipub UB Graz (Universität Graz)
Emerging Role Of Multifaceted Drugs In Diabetes Care
Chaudhari, J. B. (2025) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i6s.8507
Cruz, C. B. D. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/h5m1-fr98
Physiology of Skin, Hair, and Nails as Differentiated by Sex and Age
Patel, C. A., Ranch, K. M., Pande, S. V., Mahalakshmi, B., Allam, T., Mohamed, M. R., & Boddu, S. H. S. (2026) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-032-03596-7_2
Semaglutide and the Effects of Glucagon-like Peptide-1 on Vision
Rajput, R., Chakravarti, H. N., Kesavadev, J., KOVIL, R. R., & Rajput, S. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_28_25
Semaglutide: Scoping Review with ☸️SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsara45190890
Fukuda, S., Takata, H., Hayashi, R., Yamamoto, H., Nakae, T., Tatsumi, N., Hamamoto, H., Kobayashi, S., Ando, H., & Ishida, T. (2026) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00668
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Wang, K., Hu, Y., Jiang, Y., Fan, R., Bao, Y., Wang, S., Liang, Q., Lu, K., Xue, J., Yan, Y., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219523
2型糖尿病患者における経口セマグルチドの有効性・安全性に関する検討:多施設共同後ろ向き観察研究と多施設共同前向き非盲検並行群間無作為化比較試験による包括的評価
古澤, 翔. (2025) · Institutional Repositories DataBase (IRDB) · doi:10.14943/doctoral.k16430
Takebayashi, K., 张, 远., Miyake, Y., Ujiie, A., Yamauchi, M., Hara, K., Tsuchiya, T., & Hashimoto, K. (2024) · Institutional Repositories DataBase (IRDB)
Nanotechnological and material science for diabetics and advanced transdermal delivery
Voronova, A. (2021) · theses.fr (ABES) · doi:10.70675/c83b9043z951bz4b46z909czee7548745aca
Dahan, A. E., Azran, C., & Dahan, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040466
Yau, K. Y. T. (2025) · TSpace (University of Toronto)
Peña-Vera, A., Gutiérrez, S. D., Marrero, C. M., Figueiredo, I. V., & Abdala, S. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94020035
La révolution des nanobodies et anticorps à usage thérapeutique dans l’hémophilie
Lenting, P. J., & Denis, C. V. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.01.022
Chikamatsu, S., Sakaguchi, K., Sasaki, K., Ohtsuki, S., & Ito, S. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104335
Zhou, X., Han, F., Ma, Y., Zhong, Y., Huang, D., & Qian, H. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.177699
Clinical and economic aspects of semaglutide use in the treatment of obesity
Tibilova, A. L., Kozaeva, D. D., Aslakhanova, R. R., Tedety, V. Z., Tazurkaeva, M. Z., Gurtsieva, D. E., Kanteeva, E. E., Gabueva, M. S., Guatsaeva, V. I., Dzhigkaeva, A. M., et al. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.369
Quantitative EDTA Method for Oral Peptide Formulations using HPLC without ChelationPreprint
Dauphin, N. L., Muehlbauer, L. K., Lake, M. E., Huang, S., & Risley, D. S. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6914141
The Incretin Revolution: Transforming Metabolic Medicine Review Article
prudvika, K., & Rani., A. S. (2026) · International journal of research and scientific innovation · doi:10.51244/ijrsi.2026.1305000213
Practical Considerations for the Use of Oral Glucagon-like Peptide-1 Receptor Agonist in India
Ashraf, H., Bakshi, S., Ekatpure, H., Kumar, N. S. P., Acharyya, M., Reddy, J. N., Ghosh, J., Goel, A., Chaudhary, R., Saini, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_25_26
Gandham, D. S., Pogadapula, B. S., Roopavath, S. D., & Manyam, S. S. D. (2026) · International Journal of Research Publication and Reviews · doi:10.55248/gengpi.07.0626.17a10
Auditeau, C., Bianchini, E. P., Peyron, I., Ruty, A., Saenjamsai, P., Mariem, K., Hackeng, T. M., Christophe, O. D., Denis, C. V., Borgel, D., et al. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2894-0856
Oral Delivery of Bioactive Protein Molecules: Problems and Perspectives
Merzlyakova, N., Тихонов, С. Л., Тихонова, Н. В., Tikhonova, M. S., Semin, A. N., Kurdyumov, A. V., & Lylov, A. S. (2026) · Food Processing Techniques and Technology · doi:10.21603/2074-9414-2026-2-2644
Parra, J. L., & Llanes, F. J. G. (2026) · Zaguan (Universidad de Zaragoza)
Im, S., Lee, J., & Kim, J.-E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070826
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Hao, X., Liu, L., Li, P., Lei, C., Tong, Y., Dong, J., Liu, X., Cheng, X., Zhao, J., Min, X., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113437
As, A., Балыкова, Л. А., Zaslavskaya, K. Y., Shohin, I. E., Геннадьевна, Б. Т., Zorina, L. A., Shcherbakova, V. S., Куркин, Д. В., Koryanova, K. N., Mishchenko, E. S., et al. (2026) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2026-14-4-387-409
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
The use of alkalizers in sodium caprate-based tablets for oligonucleotide oral delivery
Marcy, S., Semling, S., Blaabjerg, L. I., Varum, F., & Lindenberg, M. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115208
Arduino, I., Iacobazzi, R. M., Pontrelli, A., Racaniello, G. F., Siliqi, D., Tiboni, M., Cutrignelli, A., Lopedota, A., & Denora, N. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127291
Mortensen, J. S., Krog, L. S., Bohr, S. S.-R., Råberg, L., Stubelius, A., Saaby, L., Hatzakis, N. S., Nguyen, D. N., Rønholt, S., & Nielsen, H. M. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.154076
Akter, S., Bergström, M., Hansson, P., Kohlbrecher, J., Doutch, J., Hossain, S., & Larsson, P. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100641
Harindranath, H., Susil, A., Osmani, R. A. M., Fatease, A. M. A., Alamri, A. H., Kumar, R., Sekar, M., & Kumar, B. R. P. (2026) · Next research. · doi:10.1016/j.nexres.2026.102334
Muzaffar, T. H., Steitieh, H., Khudadah, K., Alrandi, M., Subbarao, G., Chetty, S., Shalaby, A., & Shaghouli, A. A. (2026) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2026.100325
Simulating the Permeation of a Therapeutic Peptide through a Phospholipid Membrane
Kang, C., Stamatis, S. D., Tran, H., Rose, J. P., & Sun, R. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6c04611
Niessen, J., Koziolek, M., Borchardt, T. B., Indulkar, A. S., Ortiz, B. J., Sjöblom, M., Hedeland, M., Lennernäs, H., & Dahlgren, D. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115340
Structural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
Doosti, M., & Qaoud, M. T. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108941
Beyond the needle: engineering and industrial insight on oral delivery devices for biologics
Ji, M., Lü, Y., Arcovio, K., Wang, Y., Al‐Jamal, K. T., Bolodeoku, J., Forte, A. E., Ke, P., Shanmugam, R. K., & Alhnan, M. A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115371
The future of peptide ADMET prediction: Leveraging AI to unlock new possibilities
Liu, Q., Tan, X., Xie, F., Ouyang, D., Zeng, W., & Dong, J. N. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104809
Regulatory challenges of novel pharmaceutical excipients: A review
Al-Tal, Z., Khanfar, M., Baniali, N., & Tahat, A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108986
แนวคิดการพัฒนายา semaglutide แบบรับประทาน และการนำไปใช้ในทางคลินิก
จตุเทน, ก., ด้วงพันธุ์, พ., ปรีชานุกูล, ส., & สรวลเสน่ห์, ธ. (2020) · Thai Journal of Hospital Pharmacy
Oral delivery of proteins and peptides: current advances and future opportunities
Majjari, V. P. (2025) · Zoology, Ecology and Pharma Advances
Yadav, S., Singh, P., Purohit, M. N., Singh, S., & Singh, S. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00671-5
Li, X., Chen, Y., Chen, H., Huang, J. H., & He, B. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104826
Karunadasa, H., & Vasudevan, A. (2026) · World Journal of Translational Medicine · doi:10.5528/wjtm.124866
Alhazmi, A., & le Roux, C. W. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s637685
A Magyar Tudományos Akadémia kutatóhelyeinek 2018. évi tudományos eredményei II.
(2019) · REAL-EOD (Library of the Hungarian Academy of Sciences and the Information Center Oriental Collection)
Peptide and Macrocycle Chemistry in the Development of Metabolic and Obesity Therapeutics
Lee, S. H., Wong, Y. H., & Khatlan, S. A. D. M. (2026) · Integrative Biomedical Research · doi:10.25163/biomedical.10210960
Chen, Z., Zhou, Y., Li, G., MUTHANNA, A., d’Arqom, A., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02110-3
Obesity: oral therapy for those afraid of needles
Vignera, S. L., & Condorelli, R. A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749645
Сергеевич, А. А., Александровна, Б. Л., Яковлевна, З. К., Евгеньевич, Ш. И., Геннадьевна, Б. Т., Анатольевна, З. Л., Сергеевна, Щ. В., Владимирович, К. Д., Koryanova, K. N., Сергеевна, М. Е., et al. (2026) · Pharmacy & Pharmacology
Kneiszl, R., Alkakaei, M., Bwaila, K., Karlgren, M., Hossain, S., & Larsson, P. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103612
Yang, R., Zhang, S., Fu, Z., Yang, Y., Wang, Q., Zhou, Y., Li, J., Yang, R., Ning, S., Shi, Y., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70117
Yuan, B., Sui, Y., Li, H., Huang, J., Oh, Y. C., Zhao, Y., Li, X., Sun, Y., Liu, D., Basit, A. W., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115455
Engineering Gastroretentive Drug Delivery Systems for Improved Oral Bioavailability
Gaur, N., & Singh, S. (2026) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/0118756921480981261005111904
Sahu, L., Nayak, L., Tripathy, A., Ramachandiran, S., Gunasekaran, B., & Lokaiah, T. (2026) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100261499499
Ogiso, K., Deguchi, T., Kawade, S., Arimura, A., Nishio, Y., & Morino, K. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70477
Kwon, K., Gaidarenko, O., Chang, N., & Henderson, C. (2026) · medRxiv · doi:10.64898/2026.10.22.26365662
Lin, J., & Bratkowski, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.21.755545
Glucagon-like peptide-1 receptor agonists and risk of arrhythmias: A network meta-analysis
Barbosa, L., Oliveira, V. M. R., Ruelas, M. G., NASCIMENTO, B. R., Moreira, H. G., Nunes, M. D. C. P., Darrieux, F., Lópes, R. D., Boriani, G., & Lip, G. Y. H. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.10.052
BindingDB Entry 50022117: Binding sites and design strategies for small molecule GLP-1R agonists.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gk6
Seo, Y., & Woo, J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104843
Makuc, J., & Janić, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218295
Sandler, L. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15011548/v1
Chen, J., Chen, K., Wang, T., Lin, Y., Wang, M., & Zhang, J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111399
Mowery, S. A., Knerr, P. J., Hjøllund, K. R., Nissen, B., Olsen, A. K., Wilkens, T. L., Jakobsen, L. H., Hollesen, C., Breusova, K., Sorrell, J. E., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102470
Biopharmaceutics Classification System Class IV Drugs: Carriers and Barriers
Abouelbaqa, Y., Stephens, N. R., Löbenberg, R., & Davies, N. M. (2026) · Die Pharmazie · doi:10.31083/pharmazie56776
Ma, B., Fuhrmann, J., Pang, J., Carione, P., Chen, S., Wang, D., McKee, K. M., Wu, H., & Dening, T. J. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00821
Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering
Johns, D. G., Skataric, M., Zhou, S., Gheyas, F., Bajwa, E. K., Banka, P., Kesisoglou, F., Hunt, A., Bruce, D., Anderson, C., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70541
GLP-1 based therapy of obesity and type 2 diabetes
Holst, J. J. (2026) · Diabetology International · doi:10.1007/s13340-026-00946-x
ADMETatlas: an online database of peptide ADMET evidence toward peptide therapeutic development
Yi, J., Tian, Y., Deng, Y., Gu, X., Fu, X., Jiang, D., Lyu, A., & Cao, D. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag1147
Metadata
- Authors
- Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., Pedersen, B. L., Skyggebjerg, R. B., Benie, A. J., Strauss, H. M., Wahlund, P.-O., Bjerregaard, S., Farkas, E., Fekete, C., Søndergaard, F. L., Borregaard, J., Hartoft-Nielsen, M.-L., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S, 2760 Måløv, Denmark.
- HUN-REN Institute of Experimental Medicine (HU)
- Tufts Medical Center (US)
- Novo Nordisk A/S, 2860 Søborg, Denmark.
- Corresponding author
- Buckley, Stephen T.
- Bækdal, Tine A.
- Vegge, Andreas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2901306081
- Cited by
- 553
- References
- 40
- Citations by year
- 2026: 84 · 2025: 89 · 2024: 74 · 2023: 53 · 2022: 73 · 2021: 77 · 2020: 69 · 2019: 32 · 2018: 1
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, SNAC, gastric absorption, oral drug delivery, tablet formulation, tight junctions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adolescent, Adult, Aged, Animals, Cell Membrane, Dogs, Glucagon-Like Peptides, Epithelial Cells, Gastric Mucosa, Humans, Hydrogen-Ion Concentration, Intestinal Absorption, Male, Middle Aged, Stomach, Time Factors, Rats, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.